Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RRM2 | P31350 | 9/20 | 0.55 |
| ▸ | G6PD | P11413 | 1/20 | 0.50 |
| ▸ | RRM1 | P23921 | 1/20 | 0.47 |
| ▸ | RRM2B | Q7LG56 | 1/20 | 0.47 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6264236 | 0.85 | RRM2 (0.55) | RRM2G6PDMEN1KMT2AL3MBTL1 | |
| SCHEMBL6264240 | 0.85 | RRM2 (0.55) | RRM2G6PDMEN1KMT2AL3MBTL1 | |
| SCHEMBL31753303 | 0.83 | RRM2 (0.52) | RRM2G6PDMEN1KMT2AL3MBTL1 | |
| SCHEMBL4390542 | 0.83 | RRM2 (0.52) | RRM2G6PDMEN1KMT2AL3MBTL1 | |
| SCHEMBL8683286 | 0.79 | ALDH1A1 (0.51) | RRM2G6PDMEN1KMT2AL3MBTL1 | |
| SCHEMBL8683501 | 0.79 | RRM2 (0.48) | RRM2G6PDMEN1KMT2AL3MBTL1 | |
| SCHEMBL8683429 | 0.78 | RRM2 (0.47) | RRM2G6PDMEN1KMT2AL3MBTL1 | |
| SCHEMBL4382591 | 0.74 | RRM2 (0.67) | RRM2RRM1RRM2BCISD1KDM4E | |
| SCHEMBL7749775 | 0.74 | RRM2 (0.67) | RRM2RRM1RRM2BCISD1KDM4E | |
| SCHEMBL31753656 | 0.74 | RRM2 (0.67) | RRM2RRM1RRM2BCISD1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5721259-A | Method of using 2-formylpyridine thiosemicarbazone compounds | YALE UNIVERSITY (US) | 1998-02-24 | — | — | US | claimed |
| EP-0570294-B1 | 2-Formylpyridine thiosemicarbazone derivatives, their preparation and their use as antitumor agents | UNIV YALE (US) | 1997-07-30 | — | — | EP | claimed |
| US-5281715-A | 2-formylpyridine thiosemicarbazone compounds | YALE UNIVERSITY (US) | 1994-01-25 | — | — | US | claimed |
| EP-0570294-A1 | 2-Formylpyridine thiosemicarbazone derivatives, their preparation and their use as antitumor agents | YALE UNIVERSITY (US) | 1993-11-18 | — | — | EP | claimed |
| WO-2025260130-A1 | COMPOUNDS AND USES THEREOF | THE UNIVERSITY OF MELBOURNE (AU) | 2025-12-26 | — | — | WO | disclosed |
| US-20090298891-A1 | Methods of Treating or Preventing Cancer Using Pyridine Carboxaldehyde Pyridine Thiosemicarbazone Radiosensitizing Agents | GOVERNMENT OF THE US, AS REPRESENTED BY THE SECRETADY OF HEALTH AND HUMAN SERVICES (US) | 2009-12-03 | — | — | US | disclosed |
| EP-1951230-A2 | METHODS OF TREATING OR PREVENTING CANCER USING PYRIDINE CARBOXALDEHYDE PYRIDINE THIOSEMICARBAZONE RADIOSENSITIZING AGENTS | Government of the United States of America, as represented by the Secretary, Department of Health and Human Services (US) | 2008-08-06 | — | — | EP | disclosed |
| WO-2007035489-A2 | METHODS OF TREATING OR PREVENTING CANCER USING PYRIDINE CARBOXALDEHYDE PYRIDINE THIOSEMICARBAZONE RADIOSENSITIZING AGENTS | GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2007-03-29 | — | — | WO | disclosed |
| US-5721259-A | Method of using 2-formylpyridine thiosemicarbazone compounds | YALE UNIVERSITY (US) | 1998-02-24 | — | — | US | disclosed |
| EP-0570294-B1 | 2-Formylpyridine thiosemicarbazone derivatives, their preparation and their use as antitumor agents | UNIV YALE (US) | 1997-07-30 | — | — | EP | disclosed |
| US-5281715-A | 2-formylpyridine thiosemicarbazone compounds | YALE UNIVERSITY (US) | 1994-01-25 | — | — | US | disclosed |
| EP-0570294-A1 | 2-Formylpyridine thiosemicarbazone derivatives, their preparation and their use as antitumor agents | YALE UNIVERSITY (US) | 1993-11-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298891-A1 | Methods of Treating or Preventing Cancer Using Pyridine Carboxaldehyde Pyridine Thiosemicarbazone Radiosensitizing Agents | DPYD, NTPCR, RRM2B | RRM2 4/4885G6PD 125/4885RRM1 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.